Prothena Corp (PRTA)

• Market cap: $482M
• 1 day: 1.24%
• 5 days: 0.67%
• 1 month: -0.22%
• 3 months: -11.98%
• 6 months: 11.3%
• Year to date: -2.61%
• 1 year: -35.49%
• 5 years: -61.04%
• 10 years: -71.96%
• Sector: Healthcare
• Industry: Biotechnology

About: Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Employees: 163